Research ArticleExperimental Studies

Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models

YUKI NIWA, MAKOTO ASANO, TAKAYUKI NAKAGAWA, DAMIEN FRANCE, TARO SEMBA and YASUHIRO FUNAHASHI
Anticancer Research December 2020, 40 (12) 6699-6712; DOI: https://doi.org/10.21873/anticanres.14693

Article Information

vol. 40 no. 12 6699-6712
DOI 
https://doi.org/10.21873/anticanres.14693
PubMed 
33288563
Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received October 30, 2020
  • Revision received November 15, 2020
  • Accepted November 16, 2020
  • Published online December 7, 2020.
Copyright & Usage 
Copyright © 2020 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Author Information

  1. YUKI NIWA1,
  2. MAKOTO ASANO1,
  3. TAKAYUKI NAKAGAWA1,
  4. DAMIEN FRANCE2,
  5. TARO SEMBA1 and
  6. YASUHIRO FUNAHASHI⇑1
  1. 1Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan;
  2. 2Oncodesign, Dijon, France
  1. Correspondence to: Yasuhiro Funahashi, Tsukuba Research Laboratories, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki, 300-2635, Japan. Tel: +81 298475615, Fax: +81 298477614, e-mail: y-funahashi{at}hhc.eisai.co.jp
View Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models
YUKI NIWA, MAKOTO ASANO, TAKAYUKI NAKAGAWA, DAMIEN FRANCE, TARO SEMBA, YASUHIRO FUNAHASHI
Anticancer Research Dec 2020, 40 (12) 6699-6712; DOI: 10.21873/anticanres.14693
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Keywords